Orna Therapeutics
Orna Therapeutics is a biotechnology company focused on developing a new class of fully engineered circular RNA (oRNA) therapeutics aimed at transforming disease treatment. Founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, the company utilizes a proprietary platform that integrates innovative technology for creating circular RNAs designed to enhance protein expression. This platform also incorporates unique delivery solutions to facilitate simplified production, improved formula stability, and superior protein expression, ultimately contributing to advancements in healthcare and therapeutic applications.
ReNAgade Therapeutics is dedicated to harnessing the potential of RNA therapeutics for disease treatment through innovative gene therapy technologies. The company has developed a proprietary platform that utilizes RNA delivery systems, enabling coding, editing, and gene insertion to create novel medications. Its advanced CRISPR-Cas9 system allows for precise gene editing, minimizing off-target effects and enhancing the durability of gene therapies. This technology aims to broaden the applications of gene therapy across various medical conditions, ultimately improving safety and effectiveness for patients. By focusing on an all-RNA system, ReNAgade Therapeutics seeks to revolutionize the landscape of RNA medicines and advance healthcare solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.